A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation.


Journal

Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361

Informations de publication

Date de publication:
05 2020
Historique:
received: 10 08 2019
revised: 21 12 2019
accepted: 20 01 2020
pubmed: 6 2 2020
medline: 20 7 2021
entrez: 5 2 2020
Statut: ppublish

Résumé

This open-label non-inferiority study assessed efficacy of a common outpatient medical abortion regimen among people with pregnancies 64-70 days and 71-77 days of gestation. We defined non-inferiority by a 6% margin of method success. People with intrauterine pregnancies 64-77 days' gestational age by abdominal ultrasound seeking medical abortion at one of eight clinics and met eligibility criteria were offered participation. Consenting participants took mifepristone 200 mg followed 24-48 h later by misoprostol 800 mcg buccally, and returned after one week for provider evaluation and abdominal ultrasound to determine abortion status. Participants recorded medication use, pregnancy expulsion, daily bleeding and pain scores until the one-week follow up. Clinic staff interviewed participants prior to study discharge to assess acceptability. Seven hundred and nineteen participants were enrolled, 393 and 326 in the respective groups. Successful expulsion without surgical intervention was achieved in 92.3% of the earlier gestational age group and 86.7% of the later group (difference in proportions 5.6%, 1-sided 95% CI 9.6). Ongoing pregnancy accounted for 3.6% and 8.7% (p = 0.007) of outcomes, respectively. Participants in the 71-77 day group reported nausea and weakness more frequently. Pain, bleeding and acceptability measures between groups were similar. Although the success rate at 71-77 days of gestation was within the non-inferiority margin, we cannot rule out that it is statistically worse than in the previous gestational week. Significantly more ongoing pregnancies in the later group raise concerns about using the regimen at 71-77 days.

Identifiants

pubmed: 32014520
pii: S0010-7824(20)30028-7
doi: 10.1016/j.contraception.2020.01.009
pii:
doi:

Substances chimiques

Abortifacient Agents 0
Misoprostol 0E43V0BB57
Mifepristone 320T6RNW1F

Types de publication

Equivalence Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

302-308

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Ilana G Dzuba (IG)

Gynuity Health Projects, 220 E. 42nd Street, Suite 710, New York, NY 10017, USA. Electronic address: idzuba@gynuity.org.

Erica Chong (E)

Gynuity Health Projects, 220 E. 42nd Street, Suite 710, New York, NY 10017, USA. Electronic address: echong@gynuity.org.

Curtiss Hannum (C)

The Women's Centers, 777 Appletree Street, 7th Floor, Philadelphia, PA 19106, USA. Electronic address: channum@thewomenscenters.com.

E Steve Lichtenberg (ES)

Family Planning Associates, 659 West Washington Blvd, Chicago, IL 60661, USA. Electronic address: jodotter@aol.com.

Elba Margarita Lugo Hernández (EM)

Clinica Comunitaria Santa Catarina, Calle Nuevo León Mz. 38, Lt. 9., Col. Miguel de la Madrid, Del. Iztapalapa, 09698 Mexico City, Mexico. Electronic address: elbalugohdz@gmail.com.

Nguyen Thi Nhu Ngoc (NTN)

Center for Research and Consultancy on Reproductive Health, 16D Luy Ban Bich, Tan Thoi Hoa, Tan Phu, Ho Chi Minh City, Viet Nam. Electronic address: nhungoccrcrh@gmail.com.

Ashlesha Patel (A)

John H. Stroger, Jr. Hospital of Cook County, Department of Obstetrics and Gynecology, 1901 W Polk Street, Chicago, IL 60622, USA. Electronic address: apatel2@cookcountyhhs.org.

Gulnara Rzayeva (G)

Scientific Research Institute of Obstetrics and Gynecology, Baku 560-th block K. Kazimzadeh str. 118, Azerbaijan. Electronic address: gulnara_rzaeva@rambler.ru.

Patricio Sanhueza Smith (P)

Department of Reproductive Health, Secretariat of Health of Mexico City, Calle Altadena #23, Col. Nápoles, Del. Benito Juárez, 03810 Mexico City, Mexico. Electronic address: patriciosanhueza@prodigy.net.mx.

George Tsertsvadze (G)

David Gagua Clinic, 2/6 Ljubljana Street, Digomi Masivi, Tbilisi, Georgia. Electronic address: tsertsvadzegogi@yahoo.com.

Beverly Winikoff (B)

Gynuity Health Projects, 220 E. 42nd Street, Suite 710, New York, NY 10017, USA. Electronic address: bwinikoff@gynuity.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH